Phase 4 N=250 The Treatment of Glabellar Frown Lines
Glabellar Frown Lines
Primary: Efficacy, Measured as the Percentage of Participants Who Responded to Treatment — 95.7; 99.2 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=917 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile — 21.3; 20.6; 0.0 Percentage of participants
N/A N=175 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Forehead and Frown Lines
Facial Rhytides · Glabellar Frown Lines
Primary: Percentage of Participants Achieving a Score of None or Mild by Investigator-Assessed Facial Wrinkle Scale With Photonumeric Guide (FWS) in Forehead Lines at Maximum…
Phase 4 N=185 Treatment With Botulinum Toxin Type A (BOTOX®) in Chinese Patients With Moderate to Severe Frown Lines
Glabellar Rhytides
Primary: Percentage of Subjects With a ≥ 1-Grade Improvement From Day 1 in the Investigator Assessed Facial Wrinkle Scale of Glabellar Rhytides at Maximum Contraction — 97.1…
Phase 3 N=902 Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Glabellar Lines · Lateral Canthal Lines
Primary: Percentage of Subjects Who Achieve Grade/Level 0 or 1 on the GL Investigator Scales at Maximum Frown — 769 Participants
Phase 3 N=391 A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides
Forehead Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
Phase 3 N=684 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines
Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Participants Achieving a Grade of None or Mild at Maximum Smile Based on the Investigator Facial Wrinkle Scale Assessment of the Severity of Crow's Feet…
Phase 3 N=101 BOTOX® in the Treatment of Upper Facial Lines in Japan
Upper Facial Rhytides · Crow's Feet Lines · Glabellar Lines
Primary: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…
Phase 3 N=787 A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides
Facial Rhytides · Glabellar Rhytides
Primary: Percentage of Subjects With ≥2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at…
Phase 4 N=40 Patient Satisfaction Study of BOTOX® Cosmetic in the Treatment of Moderate to Severe Frown Lines
Glabellar Frown Lines
Primary: Percentage of Participants With Improvement in Subject Global Assessment of Change at Day 30 — 94.7; 0.00 Percentage of participants
Phase 3 N=417 BOTOX® in the Treatment of Crow's Feet Lines in China
Lateral Canthal Lines · Crow's Feet Lines
Primary: Percentage of Subjects Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…
Phase 3 N=306 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 74.0; 1.0 percentage of responders
Phase 3 N=303 Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Percentage of Subjects Who Achieved ≥ 2 Point Improvement Independently and Concurrently on Investigator and Patient Rating Scales — 73.6; 0 percentage of subjects
Phase 4 N=30 Emervel for the Correction of Lower Face Wrinkles & Folds
Nasolabial Folds · Marionette Lines · Wrinkles
Primary: Number of Subjects With Naturalness of Expression in Motion (2D Video) — 30 Participants
Phase 4 N=100 A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Upper Facial Lines
Primary: Percentage of Participants With Responder Status of 'Mostly Satisfied' or 'Very Satisfied' on the Facial Line Satisfaction Questionnaire (FLSQ) Follow Up Item 4…
Phase 2 N=124 A Study To Assess the Adverse Effects and Change in Condition of OnabotulinumtoxinA X Injection in Adult Participants With Forehead Lines
Forehead Lines
Primary: Number of Participants With Adverse Events — 10; 12; 18; 13 Participants
Phase 3 N=368 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 49.5 percentage of subjects — p=<0.0001
Phase 2 N=42 Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Glabellar Frown Lines (GL)
Primary: Investigator's Assessment of GL Severity at Maximum Frown Using the Facial Wrinkle Scale (FWS). — 1; 0; 0; 2 Participants
Phase 3 N=362 Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)
Primary: Main Period: Percentage of Glabellar Frown Line (GFL) Responders at Day 30 — 0; 52.3 percentage of subjects — p=<0.0001
Phase 3 N=446 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines
Lateral Canthus Rhytides · Crow's Feet Lines
Primary: Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile — 25.7; 1.3 Percentage of participants
Phase 3 N=271 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
Moderate to Severe Glabellar Frown Lines
Primary: Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's…
Phase 3 N=300 BOTOX® in the Treatment of Crow's Feet Lines in Japan
Lateral Canthus Rhytides · Crow's Feet Lines
Primary: Percentage of Participants Achieving None or Mild on the Investigator's Assessment of the Severity of Crow's Feet Lines (CFL) at Maximum Smile Using the Facial Wrinkle…
Phase 4 N=224 Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines
Glabellar Lines
Primary: Number of Subjects With a Treatment Response at Day 28 Based on the Injector's Assessment of the Severity of Glabellar Lines at Maximum Contraction Using the Facial…
Phase 2 N=198 AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
Glabellar Lines
Primary: Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7…
Phase 4 N=45 Patient Satisfaction With Treatment of BOTOX® Cosmetic for the Temporary Correction of Moderate to Severe Glabellar Lines
Skin Aging
Primary: The First Visit Onset of Efficacy as Measured by Physician Assessment — 2.2 Number of Days
Phase 3 N=25 Assess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines
Glabellar Frown Lines · Canthal Lines
Primary: Responders Rate Using the Global Aesthetic Improvement Scale (GAIS) at Maximum Frown (Glabellar Lines) — 100 percentage of participants
Phase 3 N=335 A Multi-Center Study Of CD07743 for the Improvement of Lateral Canthal Lines (CROW'S FEET)
Canthal Lines
Primary: Number of Responders on the Severity of Lateral Canthal Lines "at Maximum Smile". — 119; 6 Participants
Phase 3 N=413 Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination
Glabellar Frown Lines (GL) · Lateral Canthal Lines (LCL)
Primary: Percentage of Subjects With a ≥ 2-grade Improvement From Baseline on the Glabellar Lines Investigator and Subject Assessments at Maximum Frown — 0; 75; 78 Participants…
Phase 3 N=276 IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
Moderate to Severe Glabellar Frown Lines
Primary: Composite Endpoint Treatment Success (CETS) Constituted by 2 Variables: 2-point Responders at Maximum Frown (Frown as Much as Possible) at Day 30 by Investigator's…
Phase 2 N=61 Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for Treatment of Forehead Lines (Frontalis)
Frown Lines
Primary: Percentage of Participants With None or Mild in FHL Severity at Maximum Eyebrow Elevation — 85.7; 86.7; 93.8; 100 percentage of subjects